Open access
Open access
Powered by Google Translator Translator

RCT: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

15 Feb, 2021 | 00:36h | UTC

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Immunotherapy – targeted drug combination improves survival in advanced kidney cancer – Dana-Farber Cancer Institute

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.